Combination therapy for treatment of tumors comprising cancer-associated fibroblasts
OwnerSam COOPER, Allison NIXON +5inventors
InventorsSam COOPER, Allison NIXON, Max LONDON, Elizabeth KOCH, Arif JETHA, Christopher HARVEY, Michael BRISKIN
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions and methods comprising at least one TGF-0 inhibitor and at least one Activin inhibitor for use in methods of treating CAF-enriched cancers and/or fibrotic disease.
Claims32
A method for treating a solid tumor comprising cancer-associated fibroblasts (CAF) in a subject in need thereof, the method comprising simultaneously or sequentially administering to the subject a therapeutically effective dose of at least one TGF-β inhibitor and at least one Activin inhibitor.
A method for inhibiting the transformation of normal tissue fibroblasts into cancer associated fibroblasts (CAFs) in a patient in need thereof, the method comprising simultaneously or sequentially administering to the patient at least one TGF-β inhibitor and at least one Activin inhibitor.
A method of inhibiting growth of a solid tumor enriched in cancer-associated fibroblasts in a patient in need thereof, the method comprising simultaneously or sequentially administering to the patient at least one TGF-β inhibitor and at least one an Activin inhibitor.
A method for treating a fibrotic disease in a subject in need thereof, the method comprising simultaneously or sequentially administering to the subject a therapeutically effective dose of at least one TGF-β inhibitor and at least one Activin inhibitor.
A pharmaceutical composition comprising at least one TGF-β inhibitor and at least one Activin inhibitor in a pharmaceutically acceptable carrier.
32-38. (canceled)
Dependencies are inferred from the claim text.